Test Your Understanding Quiz 3

Prev
 1 / 17 
Next
Prev
 1 / 17 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • Identify which clinical features of cold agglutinin disease require treatment versus observation
  • Distinguish supportive measures from disease-modifying therapies
  • Select treatment strategies based on the dominant disease mechanism
  • Recognize clinical situations in which intervention is appropriate and match therapy to the underlying mechanism

A 72-year-old patient with known CAD reports mild fatigue but has a stable hemoglobin of 11.9 g/dL. The patient experiences occasional acrocyanosis during winter but no significant functional limitation.

Which management approach is most appropriate?

a
Immediate complement inhibition therapy
Complement inhibitors such as sutimlimab are generally reserved for patients with clinically significant hemolysis or symptomatic anemia.
b
Observation and cold-avoidance measures
Patients with mild disease (Hb ≥10–11 g/dL and manageable symptoms) are typically managed conservatively with cold avoidance and monitoring.
c
Urgent splenectomy
Splenectomy is usually ineffective in CAD because hemolysis occurs primarily in the liver rather than the spleen.
d
High-dose corticosteroids
Corticosteroids are often ineffective in CAD because the disease is driven primarily by IgM-mediated complement activation rather than IgG-mediated autoimmunity.

A patient with CAD develops worsening anemia with hemoglobin 7.6 g/dL and symptomatic fatigue.

Which mechanism is most directly responsible for the anemia?

a
Complement-mediated destruction of RBCs
Complement activation leads to RBC destruction, usually through extravascular clearance in the liver by Kupffer cells.
b
IgM-mediated RBC agglutination in peripheral vessels
Agglutination primarily causes circulatory symptoms rather than significant anemia.
c
Bone marrow suppression from autoimmune attack
Bone marrow suppression is not the primary mechanism in CAD.
d
Iron deficiency from chronic blood loss
Iron deficiency does not explain complement-positive hemolysis.

A patient with CAD has severe acrocyanosis but relatively mild anemia.

Which therapeutic approach most directly targets the dominant mechanism producing the symptoms?

a
Complement inhibition therapy
Complement inhibition primarily reduces hemolysis rather than circulatory symptoms.
b
Clone-directed B-cell therapy
lone-directed therapy (e.g., rituximab-based regimens) reduces antibody production but does not provide immediate relief of agglutination symptoms.
c
Cold avoidance and thermal protection
Avoiding cold exposure reduces IgM binding to RBCs and prevents agglutination in peripheral vessels.
d
Iron supplementation
Iron supplementation does not address the mechanism of symptoms.

Which treatment approach targets the source of antibody production in primary CAD?

a
Complement inhibition therapy
Complement inhibitors block downstream hemolysis but do not eliminate antibody production.
b
Clone-directed B-cell therapy
Clone-directed therapy targets the B-cell population producing the pathogenic IgM antibody, often using rituximab-based regimens.
c
Transfusion support
Transfusion replaces RBCs but does not modify the disease mechanism.
d
Thermal protection strategies
Thermal protection reduces symptoms but does not affect antibody production.

A patient with CAD develops worsening hemolysis following an infection.

Which mechanism most likely explains the deterioration?

a
Suppression of erythropoiesis
Suppressed erythropoiesis would worsen anemia but would not explain acute increases in hemolysis.
b
Decreased IgM antibody production
Reduced IgM production would improve disease.
c
Reduced hepatic clearance of RBCs
Reduced hepatic clearance would tend to decrease hemolysis.
d
Increased complement activation during inflammation
Inflammatory states can increase complement activity through the acute-phase response, amplifying complement-mediated hemolysis.

Which statement best explains why corticosteroids are usually ineffective in CAD?

a
CAD is primarily driven by complement activation rather than IgG-mediated autoimmunity
CAD pathophysiology is dominated by IgM-mediated complement activation, which responds poorly to corticosteroids compared with IgG-mediated warm AIHA. Steroids may occasionally be used as temporary bridging therapy but are not effective long-term treatment.
b
Corticosteroids suppress erythropoiesis
Corticosteroids do not primarily suppress erythropoiesis.
c
Corticosteroids increase IgM antibody production
Steroids do not increase IgM production.
d
Corticosteroids prevent complement deposition
Corticosteroids do not directly block complement deposition.

Why is splenectomy generally ineffective in treating CAD?

a
RBC destruction occurs primarily in the liver rather than the spleen
Complement-coated RBCs are removed mainly by hepatic macrophages (Kupffer cells) rather than splenic macrophages.
b
Complement activation cannot occur in the spleen
Complement activation occurs in the circulation.
c
IgM antibodies are produced exclusively in the spleen
IgM antibodies are produced by B cells in multiple lymphoid tissues.
d
Splenectomy increases complement activity
Splenectomy does not increase complement activity.

A patient with CAD requires RBC transfusion for symptomatic anemia.

Which precaution is most appropriate?

a
Administer transfusion at room temperature without modification
Cold blood products may trigger RBC agglutination in peripheral circulation.
b
Use warmed blood products during transfusion
Stored blood is kept at approximately 4 °C. Using a blood warmer prevents temperature-dependent IgM binding and reduces agglutination risk during transfusion.
c
Avoid transfusion entirely
Transfusion may be necessary in severe anemia.
d
Begin rituximab before transfusion
Rituximab does not prevent immediate transfusion complications.

A patient with CAD has persistent anemia despite rituximab therapy.

Which therapy most directly targets the remaining mechanism of disease?

a
Splenectomy
Splenectomy does not address complement-mediated hemolysis.
b
Corticosteroids
Corticosteroids have limited efficacy in CAD.
c
Iron supplementation
Iron supplementation does not address immune hemolysis.
d
Complement inhibition therapy
Complement inhibitors such as sutimlimab block early classical pathway activation and rapidly reduce hemolysis.

Notes

A patient with CAD reports worsening symptoms during winter but minimal problems during warmer months.

Which strategy is most appropriate as first-line management?

a
Aggressive immunosuppressive therapy
Immunosuppressive therapy is unnecessary for mild seasonal symptoms.
b
Complement inhibition therapy
Complement inhibitors are typically reserved for significant hemolysis.
c
Environmental and thermal protection
Avoiding cold exposure reduces antibody binding and agglutination.
d
Rituximab monotherapy
Rituximab is used for disease-modifying therapy when symptoms or hemolysis warrant treatment.

Sort the following interventions according to their primary purpose.

Cold avoidance
Rituximab
Thermal protection
Blood transfusion
Complement inhibition
Clone-directed therapy
Supportive measures
Disease-modifying therapies

Match the treatment strategy with its mechanistic target.

Clone-directed B-cell therapy
Thermal protection
Complement inhibition
Prevents cold-induced RBC agglutination
Reduces complement-mediated hemolysis
Decreases production of pathogenic IgM antibodies
Correct! Sorry, Incorrect.

Closing Note

Managing cold agglutinin disease requires identifying the mechanism driving the patient’s symptoms.

Circulatory symptoms arise from IgM-mediated agglutination, while anemia reflects complement-mediated hemolysis.

Effective care depends on matching the treatment to the dominant mechanism.

Prev
 1 / 17 
Next